Agenus (AGEN) Non-Current Deffered Revenue (2010 - 2026)
Agenus' (AGEN) quarterly Non-Current Deffered Revenue came in at $1.1 million in Q1 2026, little changed year-on-year from $1.1 million in Q1 2025, and little changed quarter-over-quarter from $1.1 million in Q4 2025.
Agenus (AGEN) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Agenus' Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue changed 0.0% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $1.1 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue held at $1.1 million in Q1 2026 per AGEN's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $8.7 million in Q1 2022 and bottomed at $1.1 million in Q4 2022.
- The 5-year median for Non-Current Deffered Revenue is $1.1 million (2022), against an average of $2.0 million.
- Across the five-year window, Non-Current Deffered Revenue plunged 89.79% in 2022 and changed 0.0% in 2023, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- Per Business Quant, the three latest AGEN Non-Current Deffered Revenue figures stand at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Agenus | 184.05 Mn | 177.29 Mn | 33.74 Mn | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 3.07 Mn |
| Jun 30, 2022 | 6.17 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 11.20 Mn |
| Sep 30, 2021 | 5.41 Mn |
| Jun 30, 2021 | 14.83 Mn |